Pasar al contenido principal

Heterogeneidad intra-tumoral e impacto clínico en cáncer de mama precoz HER2-positivo y triple-negativo

PI22/01017

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i en Salud
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario INSTITUTO DE INVESTIGACIONES BIOMEDICAS AUGUST PI I SUNYER (IDIBAPS)
Centro realización INSTITUTO DE INVESTIGACIONES BIOMEDICAS AUGUST PI I SUNYER (IDIBAPS)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The FLARE Score and Circulating Neutrophils in Patients with Cancer and COVID-19 Disease

  • Seguí, Elia|||0000-0001-7770-9825
  • Torres Canizales, Juan|||0000-0002-7138-5732
  • Auclin, E.
  • Casadevall, David|||0000-0002-3986-2084
  • Peiro Carmona, Sara
  • Aguilar Company, Juan|||0000-0002-9838-1950
  • García de Herreros, Marta|||0000-0001-8010-3584
  • Gorría, Teresa
  • Laguna, Juan Carlos|||0000-0002-2357-1186
  • Rodríguez, Marta
  • González, Azucena
  • Epaillard, N.|||0000-0001-7543-491X
  • Gavira, Javier|||0000-0001-6385-3519
  • Bolaño, Victor
  • Tapia, Jose C.|||0000-0001-6545-8862
  • Tagliamento, M.
  • Teixidó, C.
  • Arasanz, Hugo|||0000-0001-6838-6702
  • Pilotto, S.|||0000-0003-2229-4874
  • Lopez Castro, Rafael|||0000-0003-4770-4710
  • Mielgo-Rubio, Xabier|||0000-0002-0985-6150
  • Urbano, C.
  • Recondo, G.
  • Diaz Pavon, Mar|||0009-0001-2378-5432
  • Bluthgen, M.V.
  • Minatta, J.N.|||0000-0002-3531-1920
  • Lupinacci, L.
  • Brasó-Maristany, F.
  • Prat, A.
  • Vlagea, Alexandru|||0000-0003-3169-4597
  • Mezquita, Laura|||0000-0003-0936-7338
Inflammation and neutrophils play a central role in both COVID-19 disease and cancer. We aimed to assess the impact of pre-existing tumor-related inflammation on COVID-19 outcomes in patients with cancer and to elucidate the role of circulating neutrophil subpopulations. We conducted a multicenter retrospective analysis of 524 patients with cancer and SARS-CoV-2 infection, assessing the relationship between clinical outcomes and circulating inflammatory biomarkers collected before and during COVID-19 infection. Additionally, a single-center prospective cohort study provided data for an exploratory analysis, assessing the immunophenotype of circulating neutrophils and inflammatory cytokines. The primary endpoints were 30-day mortality and the severity of COVID-19 disease. Prior to COVID-19, 25% of patients with cancer exhibited elevated dNLR, which increased to 55% at the time of COVID-19 diagnosis. We developed the FLARE score, incorporating both tumor- and infection-induced inflammation, which categorized patients into four prognostic groups. The poor prognostic group had a 30-day mortality rate of 68%, significantly higher than the 23% in the favorable group (p < 0.0001). This score proved to be an independent predictor of early mortality. This prospective analysis revealed a shift towards immature forms of neutrophils and higher IL-6 levels in patients with cancer and severe COVID-19 infection. A pre-existing tumor-induced pro-inflammatory state significantly impacts COVID-19 outcomes in patients with cancer. The FLARE score, derived from circulating inflammatory markers, emerges as an easy-to-use, globally accessible, effective tool for clinicians to identify patients with cancer at heightened risk of severe COVID-19 complications and early mortality who might benefit most from immediate and intensive treatment strategies. Furthermore, our findings underscore the significance of immature neutrophils in the progression of COVID-19 in patients with cancer, advocating for further investigation into how these cells contribute to both cancer and COVID-19 disease.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Patritumab deruxtecan in HER2-negative breast cancer, part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response

  • Brasó-Maristany, Fara|||0000-0001-5440-9643
  • Ferrero-Cafiero, Juan Manuel|||0000-0001-8796-8812
  • Falato, Claudette
  • Martínez-Sáez, Olga|||0000-0001-8686-0236
  • Cejalvo, Juan Miguel|||0000-0002-8755-8626
  • Margelí, Mireia|||0000-0003-3594-4530
  • Tolosa, Pablo|||0000-0002-3747-4766
  • Salvador-Bofill, Francisco Javier
  • Cruz, Josefina
  • González Farré, Blanca|||0000-0002-1796-7248
  • Sanfeliu, Esther|||0000-0002-7974-3346
  • Òdena, Andreu|||0000-0003-1529-880X
  • Serra, Violeta|||0000-0001-6620-1065
  • Pardo, Francisco|||0000-0002-3067-0166
  • Luna Barrera, Ana María
  • Arumi, Miriam|||0000-0003-3329-4941
  • Guerra, Juan Antonio
  • Villacampa Javierre, Guillermo|||0000-0003-4868-6585
  • Sánchez-Bayona, Rodrigo
  • Ciruelos, Eva|||0000-0002-2796-1042
  • Espinosa-Bravo, Martín|||0000-0002-4293-3875
  • Izarzugaza, Yann
  • Galván, Patricia
  • Matito, Judit|||0000-0001-7560-7737
  • Pernas, Sonia|||0000-0002-1485-5080
  • Vidal Losada, Maria|||0000-0003-1992-5727
  • Santhanagopal, Anu
  • Sellami, Dalila
  • Esker, Stephen
  • Fan, Pang-Dian
  • Suto, Fumitaka
  • Vivancos, Ana|||0000-0003-2888-6512
  • Pascual, Tomás|||0000-0001-8431-3183
  • Prat, Aleix|||0000-0003-2377-540X
  • Oliveira, Mafalda|||0000-0001-9152-8799
Patritumab deruxtecan (HER3-DXd) exhibits promising efficacy in breast cancer, with its activity not directly correlated to baseline ERBB3/HER3 levels. This research investigates the genetic factors affecting HER3-DXd's response in women with early-stage hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer. In the SOLTI-1805 TOT-HER3 trial, a single HER3-DXd dose was administered to 98 patients across two parts: 78 patients received 6.4 mg/kg (Part A), and 44 received a lower 5.6 mg/kg dose (Part B). The CelTIL score, measuring tumor cellularity and infiltrating lymphocytes from baseline to day 21, was used to assess drug activity. Part A demonstrated increased CelTIL score after one dose of HER3-DXd. Here we report CelTIL score and safety for Part B. In addition, the exploratory analyses of part A involve a comprehensive study of gene expression, somatic mutations, copy-number segments, and DNA-based subtypes, while Part B focuses on validating gene expression. RNA analyses show significant correlations between CelTIL responses, high proliferation genes (e.g., CCNE1, MKI67), and low expression of luminal genes (e.g., NAT1, SLC39A6). DNA findings indicate that CelTIL response is significantly associated with TP53 mutations, proliferation, non-luminal signatures, and a distinct DNA-based subtype (DNADX cluster-3). Critically, low HER2DX ERBB2 mRNA, correlates with increased HER3-DXd activity, which is validated through in vivo patient-derived xenograft models. This study proposes chemosensitivity determinants, DNA-based subtype classification, and low ERBB2 expression as potential markers for HER3-DXd activity in HER2-negative breast cancer.